https://www.nasdaq.com/press-release/evusheld-long-acting-antibody-combination-retains-neutralizing-activity-against-0
https://www.nasdaq.com/press-release/evusheld-long-acting-antibody-combination-retains-neutralizing-activity-against
https://www.nasdaq.com/press-release/transgene-announces-license-option-exercise-by-astrazeneca-for-an-oncolytic-virus
https://www.nasdaq.com/press-release/samsung-biologics-and-astrazeneca-expand-strategic-manufacturing-partnership-to
https://www.nasdaq.com/press-release/calquence-reduced-the-risk-of-disease-progression-or-death-by-71-vs.-standard-of-care
https://www.nasdaq.com/press-release/enhertur-fam-trastuzumab-deruxtecan-nxki-additional-analyses-further-reinforce-ground
https://www.nasdaq.com/press-release/evusheld-formerly-azd7442-long-acting-antibody-combination-authorized-for-emergency
https://www.nasdaq.com/press-release/astrazeneca-reinforces-leadership-in-breast-cancer-at-sabcs-2021-with-new-data
https://www.nasdaq.com/press-release/biomark-to-collaborate-with-astrazeneca-pfizer-canada-and-the-iucpq-foundation-in-a-
https://www.nasdaq.com/press-release/genetron-health-announces-co-development-agreement-with-astrazeneca-rd-china-for
https://www.nasdaq.com/press-release/inaugural-asia-summit-on-global-health-successfully-explores-healthcare-landscape
https://www.nasdaq.com/press-release/inaugural-asia-summit-on-global-health-opens-today-2021-11-24
https://www.nasdaq.com/press-release/hutchmed-and-astrazeneca-initiate-sachi-phase-iii-trial-of-orpathysr-and-tagrissor
https://www.nasdaq.com/press-release/tempus-signs-strategic-collaboration-agreement-with-astrazeneca-to-advance-oncology
https://www.nasdaq.com/press-release/deutsche-banks-depositary-receipts-virtual-investor-conference-presentations-now-3
https://www.nasdaq.com/press-release/tropion-breast01-phase-3-trial-of-datopotamab-deruxtecan-initiated-in-patients-with
https://www.nasdaq.com/press-release/lokelmar-granted-fast-track-designation-in-the-us-to-reduce-cardiovascular-outcomes
https://www.nasdaq.com/press-release/inaugural-asia-summit-on-global-health-highlights-hong-kongs-advantages-2021-11-17
https://www.nasdaq.com/press-release/international-companies-to-host-live-webcasts-at-deutsche-banks-depositary-receipts-3
https://www.nasdaq.com/press-release/astrazeneca-advances-ambition-to-redefine-care-for-blood-cancer-at-ash-2021-2021-11
https://www.nasdaq.com/press-release/american-kidney-fund-announces-major-support-from-astrazeneca-to-address-health
https://www.nasdaq.com/press-release/integral-molecular-enters-into-antibody-license-agreement-with-astrazeneca-for
https://www.nasdaq.com/press-release/saga-diagnostics-enters-into-an-assay-development-agreement-with-astrazeneca-2021-11
https://www.nasdaq.com/press-release/astrazeneca-awards-30-nonprofit-organizations-through-the-act-on-health-equity
https://www.nasdaq.com/press-release/imfinzi-plus-chemotherapy-significantly-improved-overall-survival-in-1st-line
https://www.nasdaq.com/press-release/astrazeneca-announces-winners-and-recognizes-oncology-change-makers-in-third-annual
https://www.nasdaq.com/press-release/imfinzi-plus-tremelimumab-significantly-improved-overall-survival-in-himalaya-phase
https://www.nasdaq.com/press-release/tezepelumab-granted-orphan-drug-designation-in-the-us-for-eosinophilic-esophagitis
https://www.nasdaq.com/press-release/azd7442-request-for-emergency-use-authorization-for-covid-19-prophylaxis-filed-in-us
https://www.nasdaq.com/press-release/enhertur-fam-trastuzumab-deruxtecan-nxki-granted-breakthrough-therapy-designation-in
https://www.nasdaq.com/press-release/compugen-announces-milestone-payment-from-astrazeneca-triggered-by-first-patient
https://www.nasdaq.com/press-release/astrazeneca-healthcare-foundation-awards-seven-us-nonprofits-more-than-%24900k-to
https://www.nasdaq.com/press-release/astrazeneca-covid-19-and-rsv-presentations-at-idweek-2021-will-showcase-scientific
https://www.nasdaq.com/press-release/lynparzar-olaparib-in-combination-with-abiraterone-significantly-delayed-disease
https://www.nasdaq.com/press-release/imfinzi-plus-chemotherapy-tripled-patient-survival-at-three-years-in-the-caspian
https://www.nasdaq.com/press-release/enhertur-fam-trastuzumab-deruxtecan-nxki-reduced-the-risk-of-disease-progression-or
https://www.nasdaq.com/press-release/enhertur-fam-trastuzumab-deruxtecan-nxki-demonstrated-robust-and-durable-tumor
https://www.nasdaq.com/press-release/enhertur-fam-trastuzumab-deruxtecan-nxki-demonstrated-clinically-meaningful-and
https://www.nasdaq.com/press-release/imfinzi-combined-with-novel-immunotherapies-improved-clinical-outcomes-for-patients
https://www.nasdaq.com/press-release/imfinzi-and-tremelimumab-with-chemotherapy-improved-progression-free-survival-by-28
https://www.nasdaq.com/press-release/fixed-dose-combination-of-albuterol-and-budesonide-pt027-demonstrated-significant
https://www.nasdaq.com/press-release/flumistr-quadrivalent-influenza-vaccine-live-intranasal-vaccine-now-available-in-the
https://www.nasdaq.com/press-release/azd7442-provent-phase-iii-prophylaxis-trial-met-primary-endpoint-in-preventing-covid
https://www.nasdaq.com/press-release/compugen-announces-bispecific-antibody-derived-from-com902-to-enter-clinical
https://www.nasdaq.com/press-release/defence-therapeutics-selects-the-best-eight-accumtm-variants-to-optimize-its-adc
https://www.nasdaq.com/press-release/my-green-lab-certification-named-as-critical-indicator-of-progress-in-the-united
https://www.nasdaq.com/press-release/sierra-oncology-signs-exclusive-global-in-licensing-agreement-with-astrazeneca-for
https://www.nasdaq.com/press-release/saphnelo-anifrolumab-approved-in-the-us-for-moderate-to-severe-systemic-lupus
https://www.nasdaq.com/press-release/aridis-pharmaceuticals-announces-exclusive-license-of-suvratoxumab-a-phase-3-ready
https://www.nasdaq.com/press-release/moderna-set-to-join-sp-500-2021-07-15
https://www.nasdaq.com/press-release/hutchmed-announces-first-commercial-sale-of-orpathysr-in-china-triggering-a-us%2425
https://www.nasdaq.com/press-release/enwave-signs-material-transfer-agreement-with-astrazeneca-to-trial-radiant-energy
https://www.nasdaq.com/press-release/f-star-therapeutics-enters-into-exclusive-licensing-agreement-with-astrazeneca-for
https://www.nasdaq.com/press-release/tezepelumab-regulatory-submission-accepted-and-granted-fda-priority-review-in-the-us
https://www.nasdaq.com/press-release/phase-iii-pivotal-trial-of-once-weekly-exenatide-in-adolescents-aged-10-17-shows
https://www.nasdaq.com/press-release/pathai-to-present-machine-learning-based-quality-control-tool-for-her2-testing-in
https://www.nasdaq.com/press-release/proteros-enters-into-oncology-collaboration-and-license-agreement-with-astrazeneca
https://www.nasdaq.com/press-release/astrazeneca-asco-2021-data-support-ambition-to-revolutionize-cancer-outcomes-by
https://www.nasdaq.com/press-release/new-tezepelumab-data-continue-to-strengthen-profile-for-a-broad-population-of-0
https://www.nasdaq.com/press-release/amgen-announces-tezepelumab-biologics-license-application-submitted-to-u.s.-fda-2021
https://www.nasdaq.com/press-release/alchemab-to-collaborate-with-astrazeneca-to-use-alchemabs-drug-discovery-platform-for
https://www.nasdaq.com/press-release/geneseeq-and-astrazeneca-collaborate-to-build-guangzhou-bio-diagnostics-innovation
https://www.nasdaq.com/press-release/reify-health-powers-patient-recruitment-and-enrollment-across-astrazenecas-extensive
https://www.nasdaq.com/press-release/enhertur-v-trastuzumab-deruxtecan-now-available-via-the-cancer-drugs-fund-for-the
https://www.nasdaq.com/press-release/astrazeneca-announces-collaboration-with-massachusetts-general-hospital-to-accelerate
https://www.nasdaq.com/press-release/azd1222-us-phase-iii-primary-analysis-confirms-safety-and-efficacy-2021-03-24
https://www.nasdaq.com/press-release/azd1222-us-phase-iii-trial-met-primary-efficacy-endpoint-in-preventing-covid-19-at
https://www.nasdaq.com/press-release/fibrogen-provides-regulatory-update-on-roxadustat-2021-03-01
https://www.nasdaq.com/press-release/azn-march-29-deadline%3a-zhang-investor-law-alerts-investors-of-deadline-in-securities
https://www.nasdaq.com/press-release/c-o-r-r-e-c-t-i-o-n-alivecor-2021-02-16
https://www.nasdaq.com/press-release/enhertur-v-trastuzumab-deruxtecan-authorised-in-the-uk-for-the-treatment-of-her2
https://www.nasdaq.com/press-release/recombinetics-inc.-announces-neurofibromatosis-type-1-research-collaboration-with
https://www.nasdaq.com/press-release/adaptive-biotechnologies-to-collaborate-with-astrazeneca-in-mapping-the-immune
https://www.nasdaq.com/press-release/grail-announces-collaborations-with-amgen-astrazeneca-and-bristol-myers-squibb-to
https://www.nasdaq.com/press-release/compugen-announces-first-development-milestone-in-license-agreement-with-astrazeneca
https://www.nasdaq.com/press-release/astrazeneca-to-acquire-alexion-accelerating-the-companys-strategic-and-financial
https://www.nasdaq.com/press-release/fusion-pharmaceuticals-announces-collaboration-with-astrazeneca-to-develop-and
https://www.nasdaq.com/press-release/arcus-to-collaborate-with-astrazeneca-on-registrational-trial-for-domvanalimab-arcuss
https://www.nasdaq.com/press-release/first-patient-dosed-in-monalizumab-phase-3-clinical-trial-triggers-%2450m-payment-0
https://www.nasdaq.com/press-release/redhill-biopharma-adds-israel-rights-to-movantikr-from-astrazeneca-2020-10-08
https://www.nasdaq.com/press-release/lynparzar-olaparib-reduced-the-risk-of-death-by-31-in-brca1-2-or-atm-mutated
https://www.nasdaq.com/press-release/tagrisso-reduced-the-risk-of-disease-recurrence-in-the-brain-by-82-in-the-adjuvant
https://www.nasdaq.com/press-release/lynparzar-olaparib-improved-median-time-patients-lived-without-disease-progression-to
https://www.nasdaq.com/press-release/imfinzi-demonstrated-unprecedented-survival-in-unresectable-stage-iii-non-small-cell
https://www.nasdaq.com/press-release/astrazeneca-selects-veeva-vault-quality-suite-to-modernize-global-quality-management
https://www.nasdaq.com/press-release/biopharma-leaders-unite-to-stand-with-science-2020-09-08-1
https://www.nasdaq.com/press-release/biopharma-leaders-unite-to-stand-with-science-2020-09-08-2
https://www.nasdaq.com/press-release/development-of-covid-19-vaccine-azd1222-expands-into-us-phase-iii-clinical-trial
https://www.nasdaq.com/press-release/farxiga-demonstrated-unprecedented-reduction-in-the-risk-of-kidney-failure-and
https://www.nasdaq.com/press-release/renalytixai-to-collaborate-with-astrazeneca-to-improve-outcomes-for-patients-with
https://www.nasdaq.com/press-release/astrazeneca-ships-flumistr-quadrivalent-vaccine-in-the-us-for-2020-2021-flu-season
https://www.nasdaq.com/press-release/astrazeneca-partners-with-actor-and-author-tony-hale-to-build-awareness-of
https://www.nasdaq.com/press-release/daiichi-sankyo-announces-clinical-trial-collaboration-with-astrazeneca-to-evaluate
https://www.nasdaq.com/press-release/tagrisso-granted-breakthrough-therapy-designation-in-the-us-for-the-adjuvant
https://www.nasdaq.com/press-release/farxiga-met-all-primary-and-secondary-endpoints-in-groundbreaking-phase-iii-dapa-ckd
https://www.nasdaq.com/press-release/daiichi-sankyo-and-astrazeneca-enter-new-global-development-and-commercialization
https://www.nasdaq.com/press-release/breztri-aerosphere-approved-in-the-us-for-the-maintenance-treatment-of-copd-2020-07
https://www.nasdaq.com/press-release/farxiga-granted-fast-track-designation-in-the-us-for-heart-failure-following-acute
https://www.nasdaq.com/press-release/brilinta-significantly-reduced-the-rate-of-the-composite-of-stroke-and-death-in
https://www.nasdaq.com/press-release/bob-harper-and-astrazeneca-bring-virtual-series-to-heart-attack-survivors-to-inspire
https://www.nasdaq.com/press-release/brilinta-granted-fda-priority-review-for-the-reduction-of-subsequent-stroke-in
https://www.nasdaq.com/press-release/thinking-about-buying-stock-in-astrazeneca-bank-of-america-nike-paypal-or-snap-2019
https://www.nasdaq.com/press-release/biotechnology-companies-rush-develop-treatments-various-illnesses-found-globally-2019
https://www.nasdaq.com/press-release/tanabe-research-labs-announce-fda-acceptance-its-ind-application-tr1801-adc-mt-8633
